An international panel met in Washington, DC, recently under the auspices of the National MS Society’s International Advisory Committee on Clinical Trials in MS to discuss the ethics of conducting placebo-controlled trials in multiple sclerosis. This has become of increasing concern now   more »

The Phase I single ascending dose, double blind placebo controlled randomized study involved 56 healthy volunteers who received the drug in   more »

RTL1000 is a new agent that has not been previously tested in humans. It is thought that RTL may specifically control the abnormal immune response or attack against the insulation on the nerves   more »

new drug pixantrone would be studied in a multi-center phase I/II trial for treating multiple sclerosis. The company intends to   more »

placebo-controlled study will assess the safety profiles of single and multiple oral doses in healthy volunteers. "The effective treatment of multiple sclerosis remains a   more »

the independent Data Safety Monitoring Board (DSMB) for the Company's phase II MINDSET-01 trial of MBP8298 in patients with relapsing-remitting MS has completed a safety analysis and recommended that the trial continue as   more »

even though a demyelinated axon is alive, it cannot transmit motor or sensory impulses. In multiple sclerosis (MS), the myelin is believed to be damaged by the body's own immune system, rather than by   more »